Has Deepak Sahasrabudhe, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,249 in general payments to Deepak Sahasrabudhe, MD across 12 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Deepak Sahasrabudhe, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Deepak Sahasrabudhe, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Deepak Sahasrabudhe, MD

Hematology & Oncology · Rochester, NYNPI 1750301263

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,077 of the $1,249 with a category attached, or 86.2%. It is spread thinly across 9 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $441 and has fallen 65.2% since, to $153 in 2025. That places this record below the midpoint for hematology & oncology clinicians in NY, where the typical reported total is $1,337.

$1,249in general payments, 2019–2025

Across 12 payments — averaging $104.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pfizer$271
Exelixis Inc.$269
Merck$190
Stryker$153
Iovance Biotherapeutics, Inc.$137
Sanofi$107
plus $121 from 3 others

$3,443,316in research payments, 2019–2025

Across 314 payments — averaging $10,966 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Merck$2.6M
Regeneron$404K
Genentech, Inc.$297K
Bayer$105K
Array Biopharma Inc$12K
AVEO Pharmaceuticals, Inc.$3K
plus $400 from 1 others

What the payments were for

Travel & lodging$15312%
Food & beverage$1,07786%
Education$192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pfizer	2	$271
Exelixis Inc.	2	$269
Merck	2	$190
Stryker	1	$153
Iovance Biotherapeutics, Inc.	1	$137
Sanofi	1	$107
Genentech, Inc.	1	$57
Gilead	1	$45
E.r. Squibb & Sons, L.L.C.	1	$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Cabometyx$269
N/A$153
Amtagvi$137
KEYTRUDA$125
WELIREG$125
LIBTAYO$107

How this compares

$1,249 in reported general payments places this provider in the 45th percentile of 967 hematology & oncology providers in New York.

See all hematology & oncology providers in New York →

Medicare billing

Part B allowed, 2024

$37,396

Medicare patients

131

Services billed

381

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
XtandiEnzalutamide	40	$309,110
LenvimaLenvatinib Mesylate	12	$284,745
NubeqaDarolutamide	21	$258,985
Abiraterone Acetate	46	$229,434
Everolimus	18	$175,833
MektoviBinimetinib	11	$155,604
OrgovyxRelugolix	34	$87,045
Prochlorperazine Maleate	73	$850
Bicalutamide	36	$446
Prednisone	67	$240
Finasteride	18	$97

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Rochester

Alex SpyropoulosRochester$633K
Adrienne VictorRochester$143K
Brea LipeRochester$129K
Michael SchusterNew York$1.6M
Charles SawyersNew York$1.6M
Manuel Hidalgo-MedinaNew York$1.4M
Francis ArenaLake Success$1M
Sanjeev JainEast Patchogue$971K
Ross LevineNew York$968K
Perry CookBrooklyn$803K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →